Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 8 | 2023 | 620 | 1.890 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 74 | 0.990 |
Why?
|
| Endometrial Neoplasms | 2 | 2015 | 156 | 0.930 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2017 | 390 | 0.840 |
Why?
|
| Vulvar Neoplasms | 3 | 2017 | 55 | 0.810 |
Why?
|
| Gynecology | 1 | 2020 | 52 | 0.750 |
Why?
|
| Endosonography | 2 | 2023 | 97 | 0.740 |
Why?
|
| Dermatology | 1 | 2020 | 70 | 0.710 |
Why?
|
| Skin Diseases | 1 | 2020 | 145 | 0.690 |
Why?
|
| Peripheral Nerves | 2 | 2015 | 51 | 0.670 |
Why?
|
| Endometrial Hyperplasia | 2 | 2015 | 14 | 0.650 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 37 | 0.620 |
Why?
|
| Lymph Nodes | 2 | 2017 | 286 | 0.580 |
Why?
|
| Epithelioid Cells | 1 | 2015 | 15 | 0.570 |
Why?
|
| Inflammation | 1 | 2020 | 671 | 0.570 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2015 | 23 | 0.560 |
Why?
|
| Fibroma | 1 | 2015 | 42 | 0.540 |
Why?
|
| Stromal Cells | 1 | 2015 | 93 | 0.530 |
Why?
|
| Classification | 1 | 2015 | 15 | 0.530 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 65 | 0.530 |
Why?
|
| PAX2 Transcription Factor | 1 | 2015 | 22 | 0.520 |
Why?
|
| World Health Organization | 1 | 2015 | 56 | 0.520 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 537 | 0.520 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2023 | 49 | 0.480 |
Why?
|
| Blood Banks | 1 | 2012 | 25 | 0.440 |
Why?
|
| Blood Component Removal | 1 | 2012 | 17 | 0.440 |
Why?
|
| Middle Aged | 17 | 2020 | 13217 | 0.440 |
Why?
|
| Blood Transfusion | 1 | 2012 | 132 | 0.400 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2015 | 116 | 0.400 |
Why?
|
| Lipoma | 1 | 2009 | 20 | 0.370 |
Why?
|
| Female | 22 | 2020 | 28727 | 0.370 |
Why?
|
| Corpus Callosum | 1 | 2009 | 26 | 0.360 |
Why?
|
| Cerebral Palsy | 1 | 2009 | 43 | 0.360 |
Why?
|
| Humans | 31 | 2023 | 53836 | 0.360 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 429 | 0.350 |
Why?
|
| Biopsy | 4 | 2020 | 679 | 0.330 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 255 | 0.330 |
Why?
|
| Seizures | 1 | 2009 | 200 | 0.320 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2020 | 52 | 0.310 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 270 | 0.280 |
Why?
|
| Retrospective Studies | 5 | 2023 | 6330 | 0.280 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 170 | 0.280 |
Why?
|
| Adult | 13 | 2022 | 14303 | 0.270 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 3506 | 0.270 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1139 | 0.240 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1109 | 0.230 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2022 | 6 | 0.220 |
Why?
|
| Dizziness | 1 | 2022 | 14 | 0.220 |
Why?
|
| Young Adult | 5 | 2020 | 4356 | 0.220 |
Why?
|
| Consensus | 2 | 2020 | 154 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2015 | 273 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 631 | 0.200 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.200 |
Why?
|
| Vulva | 1 | 2020 | 18 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 807 | 0.200 |
Why?
|
| Research Report | 1 | 2020 | 17 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 299 | 0.190 |
Why?
|
| Aged | 7 | 2020 | 10151 | 0.190 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2019 | 14 | 0.190 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 21 | 0.180 |
Why?
|
| Risk Factors | 4 | 2015 | 3958 | 0.160 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 18 | 0.160 |
Why?
|
| Carbachol | 1 | 2018 | 33 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 67 | 0.160 |
Why?
|
| Picornaviridae Infections | 1 | 2018 | 21 | 0.160 |
Why?
|
| Keratins | 1 | 2017 | 33 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 177 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 60 | 0.160 |
Why?
|
| Skin | 1 | 2020 | 467 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 28 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2015 | 613 | 0.150 |
Why?
|
| Tracheal Neoplasms | 1 | 2016 | 9 | 0.150 |
Why?
|
| Granular Cell Tumor | 1 | 2016 | 7 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2020 | 2569 | 0.150 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 53 | 0.150 |
Why?
|
| Metabolome | 1 | 2017 | 107 | 0.140 |
Why?
|
| Pulmonary Medicine | 1 | 2015 | 15 | 0.140 |
Why?
|
| Disease Progression | 2 | 2017 | 911 | 0.140 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 42 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 257 | 0.140 |
Why?
|
| Logistic Models | 2 | 2015 | 1002 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 132 | 0.130 |
Why?
|
| Colposcopy | 1 | 2015 | 20 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2014 | 34 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 327 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2017 | 391 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2015 | 87 | 0.130 |
Why?
|
| Endometrium | 1 | 2015 | 95 | 0.130 |
Why?
|
| Adolescent | 4 | 2020 | 6918 | 0.130 |
Why?
|
| Taxoids | 1 | 2014 | 47 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 94 | 0.120 |
Why?
|
| Lung | 1 | 2018 | 512 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2014 | 84 | 0.120 |
Why?
|
| Leiomyoma | 1 | 2013 | 28 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 68 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2014 | 53 | 0.120 |
Why?
|
| Esophageal Diseases | 1 | 2013 | 24 | 0.120 |
Why?
|
| Lymphangitis | 1 | 2013 | 2 | 0.120 |
Why?
|
| Calcinosis | 1 | 2013 | 58 | 0.120 |
Why?
|
| Patient Selection | 1 | 2015 | 298 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 349 | 0.110 |
Why?
|
| Prognosis | 2 | 2015 | 2115 | 0.110 |
Why?
|
| Carcinoma | 1 | 2014 | 159 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2013 | 37 | 0.110 |
Why?
|
| Pruritus | 1 | 2013 | 52 | 0.110 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 6 | 0.110 |
Why?
|
| Male | 10 | 2022 | 27633 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 99 | 0.110 |
Why?
|
| Donor Selection | 1 | 2012 | 13 | 0.110 |
Why?
|
| Edema | 1 | 2013 | 68 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 234 | 0.100 |
Why?
|
| Dyspnea | 2 | 2022 | 81 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 326 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5645 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2376 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2009 | 111 | 0.090 |
Why?
|
| Telemedicine | 1 | 2015 | 430 | 0.090 |
Why?
|
| Blood Donors | 1 | 2009 | 37 | 0.090 |
Why?
|
| Time Factors | 1 | 2015 | 3282 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 144 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2019 | 225 | 0.080 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 162 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1296 | 0.070 |
Why?
|
| Physicians | 1 | 2009 | 253 | 0.070 |
Why?
|
| United States | 2 | 2015 | 5162 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1276 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 938 | 0.050 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 11 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2020 | 106 | 0.050 |
Why?
|
| Chest Pain | 1 | 2019 | 66 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 23 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2018 | 25 | 0.040 |
Why?
|
| Kynurenine | 1 | 2017 | 17 | 0.040 |
Why?
|
| Glutathione Disulfide | 1 | 2017 | 46 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 197 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 15 | 0.040 |
Why?
|
| Rectum | 1 | 2017 | 55 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 615 | 0.040 |
Why?
|
| Airway Obstruction | 1 | 2016 | 51 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2016 | 80 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 487 | 0.040 |
Why?
|
| Antiporters | 1 | 2015 | 18 | 0.030 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 15 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2016 | 90 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 41 | 0.030 |
Why?
|
| Cost Savings | 1 | 2015 | 72 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 8 | 0.030 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 4 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 140 | 0.030 |
Why?
|
| Carcinoma, Verrucous | 1 | 2014 | 6 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Curettage | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 286 | 0.030 |
Why?
|
| Urothelium | 1 | 2014 | 22 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 35 | 0.030 |
Why?
|
| Hematuria | 1 | 2014 | 25 | 0.030 |
Why?
|
| Mitosis | 1 | 2014 | 105 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 645 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 324 | 0.030 |
Why?
|
| Skin Tests | 1 | 2013 | 58 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 89 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2015 | 182 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 270 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 249 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 372 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 635 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 2665 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1057 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 365 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1204 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1548 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1306 | 0.020 |
Why?
|
| Liver | 1 | 2017 | 1273 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 1375 | 0.020 |
Why?
|
| Virginia | 1 | 2009 | 15 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 1640 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 687 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 198 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Self Report | 1 | 2009 | 207 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1658 | 0.010 |
Why?
|